Fosamax Global Regulatory Status: FDA Approval, Label, and Safety History

When Was Fosamax FDA Approved?

The FDA approved Fosamax (alendronate sodium) on September 27, 1995, under NDA 019588, initially for the treatment and prevention of osteoporosis in postmenopausal women. Drugs@FDA lists the complete approval history and all subsequent supplemental NDAs. That original approval made alendronate the first bisphosphonate to receive FDA clearance for postmenopausal osteoporosis in the United States.

Supplemental Approvals and Expanded Indications

After the initial 1995 approval, Merck filed supplemental NDAs that expanded the drug's labeled use significantly:

• 1995 (same cycle): Prevention of osteoporosis in postmenopausal women (lower 5 mg daily dose).
• 1997: Fosamax approved for Paget's disease of bone at 40 mg daily for six months. The FDA approval letter for this supplemental NDA is accessible through Drugs@FDA.
• 1999: Glucocorticoid-induced osteoporosis added as an indication for both men and women receiving daily systemic corticosteroids equivalent to 7.5 mg or more of prednisone.
• 2000: Treatment of osteoporosis in men approved, reflecting data showing alendronate 10 mg daily increased lumbar spine bone mineral density (BMD) by 7.1% over two years in men with osteoporosis. Pubmed indexed the key male osteoporosis trial supporting this submission.
• 2004: Once-weekly 70 mg tablet (Fosamax Plus D containing cholecalciferol) approved as a combination product under a separate NDA.

Biosimilar and Generic Entry

The first generic alendronate sodium 70 mg tablet received FDA approval in 2008 through Barr Pharmaceuticals, triggering a rapid shift in prescribing toward generic formulations. By 2010, branded Fosamax held less than 10% of the U.S. Alendronate market by volume. FDA's Orange Book records all currently approved generic alendronate products with their bioequivalence citations.

What Does the Fosamax Label Say?

The current Fosamax prescribing information (PI) is a detailed document that has been revised multiple times since 1995 in response to post-market signals. The full prescribing information PDF is available from FDA's Drugs@FDA portal.

Mechanism, Dosing, and Contraindications

Alendronate belongs to the aminobisphosphonate class. It binds hydroxyapatite in bone and inhibits osteoclast-mediated bone resorption without directly killing osteoclasts. The labeled doses are:

• 10 mg daily or 70 mg once weekly for treatment of postmenopausal osteoporosis.
• 5 mg daily or 35 mg once weekly for prevention of postmenopausal osteoporosis.
• 10 mg daily for male osteoporosis and glucocorticoid-induced osteoporosis.
• 40 mg daily for six months for Paget's disease.

Absolute contraindications in the current label include abnormalities of the esophagus that delay esophageal emptying (stricture, achalasia), inability to stand or sit upright for at least 30 minutes, hypocalcemia, and known hypersensitivity to any component. Estimated glomerular filtration rate (eGFR) below 35 mL/min/1.73 m² is listed as a contraindication due to lack of safety and efficacy data in severe renal impairment.

Boxed Warnings and Serious Adverse Reactions

The current label carries no traditional boxed warning, but it does contain a prominent section on esophageal adverse reactions placed immediately after the contraindications. The language states: "Fosamax, like other bisphosphonates administered orally, may cause local irritation of the upper gastrointestinal mucosa." Severe esophageal reactions including esophagitis, esophageal ulcers, and esophageal erosions have been reported, occasionally with esophageal stricture or perforation. The FDA's 2008 safety communication on esophageal cancer risk with oral bisphosphonates remains part of the regulatory record.

The label's Warnings and Precautions section also addresses:

1. Osteonecrosis of the jaw (ONJ): Added following a 2004-2005 post-market signal. The label instructs prescribers to consider a dental examination with appropriate preventive dentistry before initiating alendronate in patients with risk factors including cancer, corticosteroids, poor oral hygiene, or invasive dental procedures.
2. Atypical subtrochanteric and diaphyseal femoral fractures: Added in 2010 based on an FDA safety review. The label notes that these stress fractures may be bilateral, may occur with minimal or no trauma, and may be preceded by prodromal thigh or groin pain weeks to months before the fracture event.
3. Hypocalcemia: Must be corrected before initiating therapy. The label specifies calcium and vitamin D supplementation during treatment.
4. Musculoskeletal pain: Severe, incapacitating bone, joint, or muscle pain has been reported; onset ranges from one day to several months after initiating bisphosphonate therapy.

Treatment Duration Language

The label does not specify a maximum treatment duration but states that the optimal duration of use has not been determined. For patients who have been on alendronate for three to five years, the label notes that "the need for continued therapy should be re-evaluated on an individual basis." The American Society for Bone and Mineral Research (ASBMR) task force report on bisphosphonate-related atypical femoral fractures directly informed this label language.

Fosamax FDA Post-Market Surveillance and Safety Updates

Post-market surveillance of alendronate represents one of the more instructive examples of pharmacovigilance in endocrine pharmacology, covering more than 25 years of real-world safety data.

Esophageal Cancer Signal (2009-2012)

In 2009, a case series published in the New England Journal of Medicine raised concern about a possible association between oral bisphosphonate use and esophageal cancer. That correspondence appears on the NEJM site and was indexed on PubMed. The FDA initiated a formal safety review and in 2012 concluded that the available data were conflicting and did not establish a causal link. The FDA's 2012 communication summarizing this conclusion is publicly available. The label was updated to include information about reports of esophageal cancer but without a definitive causal warning.

Atypical Femur Fractures (2010 Label Update)

The atypical femur fracture signal generated substantial regulatory activity between 2008 and 2011. The FDA's safety review, supported by case reports and the Fracture Intervention Trial Long-Term Extension (FLEX), led to a March 2010 label update requiring a new subsection under Warnings and Precautions. FLEX data are published and indexed at PubMed. A subsequent 2011 FDA communication reinforced that the absolute risk remained low (estimated at 3.2-50 per 100,000 patient-years depending on duration of use) but increased with longer bisphosphonate exposure. FDA's safety communication on atypical femur fractures with bisphosphonates is publicly accessible.

ONJ Surveillance

Osteonecrosis of the jaw associated with bisphosphonate use was first described in the dental literature in 2003 and escalated quickly in post-market adverse event reports to FDA. A landmark case series by Marx published in the Journal of Oral and Maxillofacial Surgery remains widely cited. The FDA requested label updates in 2004 and again in 2005. The reported incidence in osteoporosis patients taking oral bisphosphonates is estimated at 0.001% to 0.01% per year, substantially lower than in oncology patients receiving intravenous bisphosphonates at higher doses. Estimates from a position paper by the American Association of Oral and Maxillofacial Surgeons are indexed on PubMed.

FDA Sentinel System Monitoring

Alendronate is among the drugs monitored through the FDA Sentinel System, a post-market active surveillance network drawing on data from more than 100 million covered lives. The FDA Sentinel System overview is described at the FDA website. Sentinel queries on bisphosphonate safety have examined atypical fractures, cardiovascular outcomes, and renal signals in a real-world population far larger than any individual clinical trial.

The Key Clinical Trial: FIT and Its Regulatory Significance

No discussion of Fosamax's regulatory record is complete without the Fracture Intervention Trial (FIT), which supplied the primary efficacy data supporting the osteoporosis treatment indication.

FIT Design and Results

FIT was a randomized, double-blind, placebo-controlled trial enrolling women aged 55-81 with low femoral neck BMD. The primary FIT publication in JAMA (1998) is available on PubMed. The trial had two arms: the spine fracture arm enrolled 2,027 women with at least one existing vertebral fracture, and the clinical fracture arm enrolled 4,432 women without an existing vertebral fracture at baseline.

Key efficacy results from the vertebral fracture arm at 36 months:

• Hip fracture risk reduced by 47% (relative risk 0.49, 95% CI 0.23-0.99) vs. Placebo. JAMA 1998, PubMed ID 9847152.
• Clinical vertebral fracture risk reduced by 55%.
• Any clinical fracture risk reduced by 28%.

Lumbar spine BMD increased by 8.8% vs. 0.6% for placebo at 36 months. These results formed the core of Merck's NDA efficacy package reviewed by FDA's Division of Metabolism and Endocrinology Products.

Regulatory Interpretation of FIT

The FDA's medical review for the original NDA noted that FIT was the largest bisphosphonate fracture-outcome trial conducted to that point. The agency accepted surrogate BMD endpoints for the prevention indication while requiring fracture-outcome data for the treatment indication, setting a precedent followed by subsequent bisphosphonate NDAs. FDA's published guidance on developing drugs for treatment of osteoporosis references the evidentiary standard established in part by the FIT data package.

The following decision framework summarizes the regulatory milestones and corresponding label changes for alendronate and may serve as a quick reference for clinicians reviewing a patient's bisphosphonate history.

| Year | Regulatory Event | Label Change | |------|-----------------|--------------| | 1995 | FDA approval NDA 019588 | Initial PI; esophageal precautions | | 1997 | Paget's disease indication | 40 mg/day 6-month regimen added | | 1999 | Glucocorticoid osteoporosis | Men and women, 5 mg/10 mg doses | | 2000 | Male osteoporosis | 10 mg daily added | | 2004-2005 | ONJ post-market signal | ONJ warning added to W&P | | 2008 | Generic entry; esophageal cancer signal | FDA safety review initiated | | 2010 | ASBMR task force report; FLEX data | Atypical femur fracture warning added | | 2011 | FDA safety communication | Treatment duration reassessment language | | 2012 | FDA concludes esophageal cancer review | Conflicting data noted; label updated |

EMA and International Regulatory Status

Alendronate is authorized in all 27 European Union member states and holds a centralized European Medicines Agency (EMA) assessment through reference member state procedures.

EMA EPAR and Periodic Safety Reviews

The EMA's European Public Assessment Report (EPAR) for alendronate-containing products documents the scientific basis for authorization and all post-authorization safety updates. The EMA conducts Periodic Safety Update Report (PSUR) reviews at defined intervals, and the alendronate PSURs have addressed the same ONJ, atypical fracture, and esophageal signals reviewed by FDA. The EMA's product page for alendronate is accessible through the EMA website.

European labeling for alendronate (SmPC, Summary of Product Characteristics) aligns closely with the FDA PI on contraindications and warnings, though terminology follows EMA conventions. The SmPC lists esophageal reactions, ONJ, and atypical femoral fractures under Section 4.4 (Special Warnings and Precautions for Use) and mirrors the FDA's treatment duration guidance recommending re-evaluation after three to five years.

Status in Other Major Markets

• Canada (Health Canada): Alendronate received Notice of Compliance from Health Canada and is listed in the Drug Product Database. Health Canada issued an advisory on atypical femur fractures in 2012, consistent with FDA's 2010-2011 communications.
• United Kingdom (MHRA): Post-Brexit, the Medicines and Healthcare products Regulatory Agency (MHRA) maintains its own marketing authorization for alendronate generics. The MHRA Yellow Card scheme has received reports consistent with the global safety profile.
• Australia (TGA): The Therapeutic Goods Administration lists alendronate on the Australian Register of Therapeutic Goods (ARTG). Product Information documents mirror ONJ and atypical fracture warnings.
• Japan (PMDA): The Pharmaceuticals and Medical Devices Agency approved alendronate and has issued risk management plans addressing ONJ risk, which carries heightened attention in Japanese post-marketing surveillance given differences in jaw surgery practice patterns.

Alendronate Safety: What the Evidence Actually Shows

Beyond label-language, the clinical picture of alendronate safety comes from a combination of randomized trial extensions, observational databases, and pharmacoepidemiologic studies.

Cardiovascular Safety

Early observational data raised questions about atrial fibrillation risk with bisphosphonate use. A nested case-control study published in the Archives of Internal Medicine (2007) reported an increased odds ratio of 1.86 for atrial fibrillation. That study is indexed on PubMed. Subsequent larger analyses, including a Danish cohort study of over 36,000 bisphosphonate users, found no statistically significant association. The Danish cohort study is indexed on PubMed. The FDA's safety review concluded the signal was not substantiated, and no cardiovascular warning was added to the label.

Renal Safety

Alendronate's renal safety profile differs from that of intravenous bisphosphonates. Oral alendronate is not associated with acute phase reactions or acute tubular necrosis at standard doses. However, the label contraindication for eGFR below 35 mL/min/1.73 m² reflects the absence of trial data in severe renal impairment, not a documented harm signal at that threshold. A 2018 systematic review in the Clinical Journal of the American Society of Nephrology evaluated bisphosphonate safety across GFR strata.

Fracture Efficacy Over Extended Use

The FLEX trial (Fracture Intervention Trial Long-Term Extension) randomized women who had completed FIT to continue alendronate for five additional years or switch to placebo. FLEX is published in JAMA (2006) and indexed on PubMed. Women who continued alendronate did not show statistically significant reductions in total clinical fractures compared to those who discontinued, with one exception: women with a femoral neck T-score below minus 2.5 at the time of discontinuation had a significantly higher rate of clinical vertebral fracture if they stopped treatment. This finding directly supports the label's individualized reassessment language and forms the clinical basis for the "drug holiday" concept endorsed by professional societies.

The American Society for Bone and Mineral Research task force, in its 2016 report, stated: "For patients who have been treated for 5 years with oral bisphosphonates and are at low risk (no fractures during therapy, T-score above -2.5), drug holiday can be considered." That report is indexed on PubMed.

Gastrointestinal Tolerability Data

Upper GI tolerability remains the most common reason for alendronate discontinuation in real-world practice. The Fosamax Actonel Comparison Trial (FACT, 2004) compared alendronate 70 mg weekly with risedronate 35 mg weekly in 1,053 postmenopausal women over one year and reported similar upper GI adverse event rates between agents. FACT is published in Current Medical Research and Opinion and indexed on PubMed. Gastrointestinal tolerability is substantially improved by strict adherence to administration instructions: taking alendronate with 6-8 ounces of plain water only, remaining upright for at least 30 minutes, and avoiding food, beverages, or other medications during that period.

Prescribing Considerations Informed by the Regulatory Record

Patient Selection Based on Label Criteria

The full regulatory history translates into specific patient selection guidance. Patients with active upper GI disease, inability to comply with upright posture requirements, eGFR below 35 mL/min/1.73 m², uncorrected hypocalcemia, or planned invasive dental procedures require evaluation before alendronate is initiated. The Endocrine Society's clinical practice guideline on osteoporosis in postmenopausal women addresses patient selection criteria.

Monitoring Requirements

The label does not mandate specific laboratory monitoring intervals, but standard clinical practice based on guidelines includes:

• Baseline serum calcium, phosphate, and renal function before initiation. Endocrine Society guideline, PubMed indexed.
• BMD measurement by DEXA at baseline and again at two years for treatment monitoring.
• Re-evaluation of fracture risk at three to five years to determine whether a drug holiday is appropriate for lower-risk patients.

Drug Holiday Protocol

For patients who have completed three to five years of oral alendronate and are deemed lower risk (no incident fractures, stable BMD, T-score above minus 2.5), a two- to three-year drug holiday is supported by FLEX data and professional society guidance. Patients with persisting high fracture risk, defined as a T-score below minus 2.5 at the femoral neck or a history of hip or vertebral fracture, should generally continue therapy rather than pause it. The ASBMR task force report (2016) provides the specific risk-stratification thresholds for this decision.